{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T07:17:31Z","timestamp":1785309451124,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urology.2020.06.017","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:54:27Z","timestamp":1593176067000},"page":"52-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Optimizing Nonsurgical Treatments of Overactive Bladder in the United States"],"prefix":"10.1016","volume":"145","author":[{"given":"Benjamin M.","family":"Brucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane K.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.06.017_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/030079907X159533","article-title":"Impact of overactive bladder on women in the United States: results of a national survey","volume":"23","author":"Dmochowski","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2020.06.017_bib0004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","article-title":"The impact of overactive bladder, incontinence, and other lower urinary tract symptoms on quality of life, work productivity, sexuality, and emotional well-being in men and women: results from the EPIC study","volume":"101","author":"Coyne","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.06.017_bib0005","first-page":"S98","article-title":"Impact of overactive bladder on work productivity in the United States: results from EpiLUTS","volume":"15","author":"Sexton","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.urology.2020.06.017_bib0006","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.06.017_bib0007","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2016.07.013","article-title":"The relationship between anxiety and overactive bladder or urinary incontinence symptoms in the clinical population","volume":"98","author":"Lai","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.06.017_bib0008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12894-016-0179-x","article-title":"The relationship between depression and overactive bladder\/urinary incontinence symptoms in the clinical OAB population","volume":"16","author":"Lai","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0009","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. Available at:https:\/\/www.auanet.org\/guidelines\/overactive-bladder-(oab)-guideline. Accessed July 23, 2019.","DOI":"10.1097\/JU.0000000000000309"},{"key":"10.1016\/j.urology.2020.06.017_bib0010","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.4586","article-title":"CUA guideline on adult overactive bladder","volume":"11","author":"Corcos","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urology.2020.06.017_bib0011","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.jogc.2017.11.005","article-title":"No. 283-treatments for overactive bladder: focus on pharmacotherapy","volume":"40","author":"Geoffrion","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.urology.2020.06.017_bib0012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/M13-2410","article-title":"Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians","volume":"161","author":"Qaseem","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urology.2020.06.017_bib0013","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/nau.23551","article-title":"6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and faecal incontinence","volume":"37","author":"Abrams","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0014","unstructured":"National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NG123. 2019. Available at:https:\/\/www.nice.org.uk\/guidance\/ng123. Accessed July 23, 2019."},{"key":"10.1016\/j.urology.2020.06.017_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bju.13187","article-title":"Guideline of guidelines: urinary incontinence","volume":"117","author":"Syan","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.06.017_bib0016","first-page":"484","article-title":"Primary nonadherence to overactive bladder medications in an integrated managed health care system","volume":"23","author":"Rashid","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.urology.2020.06.017_bib0017","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00192-019-04022-8","article-title":"Updating the evidence of drugs to treat overactive bladder: a systematic review","volume":"30","author":"Hsu","year":"2019","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2020.06.017_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2296-15-96","article-title":"The patient perspective on overactive bladder: a mixed-methods needs assessment","volume":"15","author":"Filipetto","year":"2014","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.urology.2020.06.017_bib0019","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/nau.23719","article-title":"Association between overactive bladder treatment and falls among older adults","volume":"37","author":"Jayadevappa","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0020","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","article-title":"Real-world characteristics of elderly patients with overactive bladder in the United States","volume":"32","author":"Ganz","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2020.06.017_bib0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.urology.2017.03.058","article-title":"Overactive bladder is strongly associated with frailty in older individuals","volume":"106","author":"Suskind","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.06.017_bib0022","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1742-1241.2009.02078.x","article-title":"Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence","volume":"63","author":"Wyman","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2020.06.017_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/nau.23244","article-title":"Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms","volume":"37","author":"Newman","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0024","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1590\/1806-9282.63.12.1032","article-title":"Pelvic floor muscle training for overactive bladder symptoms \u2013 a prospective study","volume":"63","author":"Fitz","year":"2017","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.urology.2020.06.017_bib0025","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00192-007-0525-3","article-title":"Clarification and confirmation of the knack maneuver: the effect of volitional pelvic floor muscle contraction to preempt expected stress incontinence","volume":"19","author":"Miller","year":"2008","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.urology.2020.06.017_bib0026","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.1991.03460050063021","article-title":"Efficacy of bladder training in older women with urinary incontinence","volume":"265","author":"Fantl","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2020.06.017_bib0027","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/nau.23016","article-title":"Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet over-active bladder. A 4-year follow-up","volume":"36","author":"Azuri","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0028","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2522\/ptj.20080387","article-title":"Adherence to behavioral interventions for urge incontinence when combined with drug therapy: adherence rates, barriers, and predictors","volume":"90","author":"Borello-France","year":"2010","journal-title":"Phys Ther"},{"key":"10.1016\/j.urology.2020.06.017_bib0029","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/nau.22796","article-title":"2014 consensus statement on improving pelvic floor muscle training adherence: International Continence Society 2011 State-of-the-Science Seminar","volume":"34","author":"Dumoulin","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2020.06.017_bib0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/AOG.0000000000000851","article-title":"Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis","volume":"125","author":"Reynolds","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2020.06.017_bib0031","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","article-title":"The placebo effect in overactive bladder syndrome","volume":"8","author":"Mangera","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0032","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.06.017_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.archger.2018.09.005","article-title":"Antimuscarinic use and discontinuation in an older adult population","volume":"80","author":"Vouri","year":"2019","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.urology.2020.06.017_bib0034","doi-asserted-by":"crossref","first-page":"E378","DOI":"10.5489\/cuaj.5032","article-title":"How long do we have to treat overactive bladder syndrome? A questionnaire survey of Canadian urologists and gynecologists","volume":"12","author":"Przydacz","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urology.2020.06.017_bib0035","first-page":"291","article-title":"Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan","volume":"14","author":"D'Souza","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.urology.2020.06.017_bib0036","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jcph.890","article-title":"Antimuscarinic use in females with overactive bladder syndrome increases the risk of depressive disorder: a 3-year follow-up study","volume":"57","author":"Chung","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.urology.2020.06.017_bib0037","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2020.06.017_bib0038","first-page":"1","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"00","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.urology.2020.06.017_bib0039","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MLR.0000000000000858","article-title":"Impact of new medications and $4 generic programs on overactive bladder treatment among older adults in the United States, 2000\u20132015","volume":"56","author":"Kinlaw","year":"2018","journal-title":"Med Care"},{"key":"10.1016\/j.urology.2020.06.017_bib0040","series-title":"MYRBETRIQ\u00ae (Mirabegron Extended-Release Tablets) Prescribing Information","year":"2018"},{"key":"10.1016\/j.urology.2020.06.017_bib0041","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0042","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0043","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.06.017_bib0044","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0046","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BEDSIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0047","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.06.017_bib0048","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre, phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0049","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/2051415817706045","article-title":"Evaluating the efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, for the treatment of overactive bladder: systematic review and network meta-analysis","volume":"10","author":"Fest","year":"2017","journal-title":"J Clin Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0051","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b23-adrenoceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled, phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0052","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0053","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmonson","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.urology.2020.06.017_bib0054","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0055","doi-asserted-by":"crossref","first-page":"1831\u20101840","DOI":"10.1111\/j.1464-410X.2011.10624.x","article-title":"Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1-blocker treatment for lower urinary tract symptoms","volume":"109","author":"Kaplan","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.06.017_bib0056","doi-asserted-by":"crossref","first-page":"637\u2010649","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0057","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2490-14-84","article-title":"Tolterodine extended release in the treatment of male OAB\/storage LUTS: a systematic review","volume":"14","author":"Gacci","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2020.06.017_bib0058","doi-asserted-by":"crossref","first-page":"e18802","DOI":"10.1097\/MD.0000000000018802","article-title":"The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis","volume":"99","author":"Su","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urology.2020.06.017_bib0059","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bju.13025","article-title":"Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder","volume":"116","author":"Malde","year":"2015","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520307391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520307391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:28:47Z","timestamp":1758767327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520307391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":59,"alternative-id":["S0090429520307391"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.06.017","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Nonsurgical Treatments of Overactive Bladder in the United States","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}